Vepsitamab

Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation[1].

Product Specifications

CAS Number

[2413453-53-7]

Product Name Alternative

AMG 199

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vepsitamab.html

Purity

98.44

Solubility

10 mM in DMSO

Smiles

[Vepsitamab]

Molecular Weight

(105 kDa)

References & Citations

[1]Joseph Chao, et al. Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. 2020 ASCO Annual Meeting I.